Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 21
Phase 31

Trial Status

Completed1

Role Distribution

Other Roles1

Activity Timeline

Clinical Trials (1)

NCT00354120Phase 2/3Completed
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
Acute Myeloblastic LeukemiaChronic Myeloid LeukemiaLympho-proliferative Diseases+3 more
Studychair

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Jorge Cortes, MD

M.D. Anderson Cancer Center

Related
24 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL PositivePrecursor Cell Lymphoblastic Leukemia-Lymphoma+1 more
Similarity Score20%

Jorge E Cortes, MD

M.D. Anderson Cancer Center

Related
8 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL PositivePrecursor Cell Lymphoblastic Leukemia-Lymphoma+1 more
Similarity Score20%

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteMyelodysplasia+1 more
Similarity Score20%

David Avigan, MD

Beth Israel Deaconess Medical Center

Related
17 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myelogenous, Chronic, BCR-ABL Positive+1 more
Similarity Score20%

Beata Holkova, MD

Massey Cancer Center

Related
3 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL Positive
Similarity Score15%

Yifan Zhai, MD, PhD

Ascentage Pharma Group Inc.

Related
14 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic, BCR-ABL PositivePrimary Myelofibrosis
Similarity Score15%

Qifa Liu

Nanfang Hospital, Southern Medical University

Related
33 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myelogenous, Chronic, BCR-ABL Positive
Similarity Score15%

Richard W Childs, M.D.

National Heart, Lung, and Blood Institute (NHLBI)

Related
15 trials

Shared therapeutic areas:

Leukemia, Myelogenous, Chronic, BCR-ABL PositivePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, Acute
Similarity Score15%

Yves Beguin, MD, PhD

CHU-ULg

Related
7 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Acute
Similarity Score15%

Brigitte C Widemann, M.D.

National Cancer Institute (NCI)

Related
19 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, Acute
Similarity Score10%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT00354120Phase 2/3StudyChair

Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant

Acute Myeloblastic LeukemiaChronic Myeloid LeukemiaLympho-proliferative Diseases+3 more
Completed

All 1 trials loaded